Stanford University

Showing 1-4 of 4 Results

• 

  Sean Ku Wang, MD

  Clinical Instructor, Ophthalmology
  

  BioDr. Sean Ku Wang is a board-certified ophthalmologist and fellowship-trained retina specialist with Stanford Health Care and an Assistant Professor of Ophthalmology at Stanford University.
  
  Dr. Wang specializes in treating diseases of the retina and macula, including age-related macular degeneration, diabetic retinopathy, central serous chorioretinopathy, and retinal vascular occlusions. He is committed to providing individualized, high-quality care to achieve the best possible outcomes for his patients.
  
  Dr. Wang’s research aims to accelerate the development of safe and effective genetic therapies. By integrating approaches from genetics, immunology, synthetic biology, computer science, and medicine, his lab seeks to discover and translate new treatments for human diseases with an emphasis on blinding disorders.
  
  Dr. Wang has been recognized as a STAT Wunderkind, Forbes 30 Under 30, and a recipient of the American Society for Clinical Investigation Emerging-Generation Award and Burroughs Wellcome Fund Career Award for Medical Scientists among other honors.
• 

  Taia T. Wang, MD, PhD, MSCI

  Associate Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology
  

  Current Research and Scholarly InterestsLaboratory of Mechanisms in Human Immunity and Disease Pathogenesis
• 

  Xinnan Wang

  Professor of Neurosurgery
  

  Current Research and Scholarly InterestsMechanisms underlying mitochondrial dynamics and function, and their implications in neurological disorders.
• 

  Robert Waymouth

  Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
  

  BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
  
  Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
  
  Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
  
  The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines.